Drug intelligence / Profile preview

fludarabine + cyclophosphamide + rituximab + bendamustine

Development stage: Unknown
Lead developer: Bayer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

This is not a standard combination therapy. The search results indicate that these drugs are used in different combinations for treating chronic lymphocytic leukemia (CLL) and other lymphoid malignancies, but not all four together as a single regimen. Common combinations include FCR (fludarabine, cyclophosphamide, rituximab) and BR (bendamustine, rituximab), as well as FBR (fludarabine, bendamustine, rituximab).

Targets

CD20 (B-lymphocyte antigen CD20)DNA

Beyond the preview

Go deeper on fludarabine + cyclophosphamide + rituximab + bendamustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fludarabine + cyclophosphamide + rituximab + bendamustine.

Explore the full profile